Microba Life Sciences Limited
MAP
Rank in Stocks
#27262
Microba Life Sciences Limited, established in Brisbane, Australia, in 2017,... Microba Life Sciences Limited, established in Brisbane, Australia, in 2017, specializes in providing sophisticated microbiome testing and analytical services. These offerings reach clinicians, individual consumers, and research customers across key international markets, including Australia, Europe, New Zealand, the United Arab Emirates, the United Kingdom, and the United States. The company delivers pathology, therapeutic, and diagnostic solutions deeply rooted in human gut microbiome science. Central to its operations is a comprehensive Databank, invaluable for unearthing therapeutic leads, fostering consumer health advancements, and identifying crucial diagnostic biomarkers. Moreover, Microba leverages a data-driven therapeutics platform to engineer innovative monoclonal microbial cell therapies aimed at treating inflammatory bowel disease, enhancing cancer immunotherapy, and managing autoimmune disorders.
Share Price
$0.02449871
Last synced: 2026-11-13
Market Cap
$15.09M
Change (1 day)
2.27%
Change (1 year)
-47.28%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Microba Life Sciences Limited (MAP)
Category
Healthcare
P/S ratio for Microba Life Sciences Limited (MAP)
P/S ratio as of November 2026 TTM: 1.81
According to Microba Life Sciences Limited's latest financial reports and stock price, its current price-to-sales ratio (TTM) is 1.81. At the end of 2025 the company had a P/S ratio of 2.43.
P/S ratio history for Microba Life Sciences Limited from 2019 to 2026
P/S ratio at the end of each year
| Year | P/S Ratio | Change |
|---|---|---|
| 2026 (TTM) | 1.81 | -25.44% |
| 2025 | 2.43 | -55.71% |
| 2024 | 5.49 | -68.43% |
| 2023 | 17.39 | 48.63% |
| 2022 | 11.70 | -54.51% |
| 2021 | 25.73 | -22.06% |
| 2020 | 33.01 | -37.16% |
| 2019 | 52.53 | 0.00% |
P/S ratio for similar companies or competitors
| Company | P/S Ratio | P/S Ratio Difference | Country |
|---|---|---|---|
| 5.48 | 202.41% |
US
|
|
| 6.40 | 253.34% |
US
|
|
| 7.64 | 321.53% |
CN
|
|
| 11.90 | 556.84% |
US
|
|
| 6.65 | 267.24% |
US
|
Questions about Microba Life Sciences Limited's P/S ratio
What is Microba Life Sciences Limited's P/S ratio?
Microba Life Sciences Limited's P/S ratio is 1.81, as of Nov 2026.
What was Microba Life Sciences Limited's P/S ratio in 2025?
In 2025, Microba Life Sciences Limited's P/S ratio was 2.43, compared with 5.49 in 2024.
How has Microba Life Sciences Limited's P/S ratio changed since 2020?
From 2020 to 2025, Microba Life Sciences Limited's P/S ratio was highest in 2020 (33.01) and lowest in 2025 (2.43).
How does Microba Life Sciences Limited's P/S ratio compare with similar companies?
Microba Life Sciences Limited's P/S ratio (1.81) is lower than that of all 5 similar companies listed above. The highest among them is IDEXX Laboratories, Inc., with 11.90.